about
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.Research on anisotropy of fusion-produced protons and neutrons emission from high-current plasma-focus discharges.Therapeutics and prion disease: can immunisation or drugs be effective?Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivoDifferential molecular chaperone response associated with various mouse adapted scrapie strains.Disease modifying approaches for Alzheimer's pathology.Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivoThe effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice.1MeTIQ provides protection against Aβ-induced reduction of surface expression of synaptic proteins and inhibits H₂O₂-induced oxidative stress in primary hippocampal neurons.Circulating angiogenic cells and Alzheimer's disease: contribution of the bone marrow to the pathogenesis of the disease.APOE genotype and Alzheimer's immunotherapy.Rat's claustrum shows two main cortico-related zones.Visual zone of the claustrum shows localizational and organizational differences among rat, guinea pig, rabbit and cat.Reply: To PMID 24687915.Long-term changes in calbindin D(28K) immunoreactivity in the rat hippocampus after cardiac arrest.Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.Targeting prion amyloid deposits in vivo.18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.Pattern of neuronal loss in the rat hippocampus following experimental cardiac arrest-induced ischemia.Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology.Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.Characteristics of four-channel Cherenkov-type detector for measurements of runaway electrons in the ISTTOK tokamakCherenkov-type diamond detectors for measurements of fast electrons in the TORE-SUPRA tokamakUse of Cherenkov-type detectors for measurements of runaway electrons in the ISTTOK tokamakMass- and energy-analyses of ions from plasma by means of a miniature Thomson spectrometerNote: Measurements of fast electrons in the TORE-SUPRA tokamak by means of modified Cherenkov-type diamond detectorAnti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal DegradationTwo Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment)Editorial: Translational Control of APP Expression for Alzheimer Disease Therapy
P50
Q33248701-E9950471-2C0C-460D-89B4-5341195A73A6Q34240270-97F0E323-BDDE-4D62-B550-6536E44AEF2AQ34584517-E1A8918C-ACC4-421A-96CC-EB8505B6DFCEQ35067938-8EF36917-C696-4A43-AD80-6D43DC531E5FQ35103136-4D23933D-2264-4039-B41A-3162FFB47B74Q35552488-77BEBEF1-E9C9-45CB-B416-2600060D6D72Q36107290-8B4A693B-F555-495D-8573-EDC4ADD78C45Q36271462-5DC21BE3-05C3-4A73-AD11-D9F115893259Q36716598-197071D0-84CF-4F74-8D4D-BBE720871130Q36879333-D365886A-9BC4-4C04-B1A1-64A731EF7928Q37267798-E128CBF8-5E02-44E5-802C-F165BB63AA0AQ37415302-246C7E23-088A-4D8A-B757-6911B95C4903Q37615879-9DBD7AC1-AA84-4588-8058-5A8BE500793EQ38784401-5F5A3C0D-DB95-45FA-8A2D-DEE03F3DC6EAQ40003927-21D50652-4FD4-4645-9CE0-30FD87BE40A0Q41917796-30F544F7-E3E5-42D9-B044-F840FF32A1C3Q42335749-85142480-4635-42AC-B6D7-52BCA75E5018Q42439717-EC445762-E637-4886-A566-25EFC385F2C9Q42458879-7370954F-AA90-459B-9BF6-BC9DA9529680Q43046090-4D164688-9BF8-4132-A9F5-32802516F063Q43901318-940C6E3E-2B4C-4BC7-B8AC-59994FF0497DQ44937300-34FDCBCB-572B-46CA-A031-172EA024C1A8Q45004848-C574DC79-6AE1-4E96-8737-7E2E7C5DA87DQ47549851-1BA1F5CA-2640-421C-A765-CC20AA764D0DQ48104452-331D4612-AA49-4E45-9F63-BE2DDF0A72F0Q48294073-2F501FCD-68EA-4E2A-A6D6-25D3A4C8B0E2Q48801542-7818CD38-7DD7-44F3-B49C-D2F8F8DDB12FQ82226838-1DE63E92-421A-4721-A26C-785358BA1074Q82697158-8AE84DD4-9822-4B7F-BD76-4DB99C906885Q82778963-7CC5C5A7-BCD2-48B0-926D-91C8DC73E4F6Q83962495-98FACD7A-B122-433E-B3B3-48FDF680F351Q86072858-E75AE2A6-A1D2-4556-8A62-7836715A9976Q89484053-F295C6D0-E1B6-43C6-B0BA-8E714766E21CQ91250239-A89C32E6-42AA-402C-97D0-E47F72545EA7Q92052671-CBD9D2E3-40D9-43B5-88F9-C857820E8BCF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin J Sadowski
@ast
Martin J Sadowski
@en
Martin J Sadowski
@es
Martin J Sadowski
@nl
Martin J Sadowski
@sl
type
label
Martin J Sadowski
@ast
Martin J Sadowski
@en
Martin J Sadowski
@es
Martin J Sadowski
@nl
Martin J Sadowski
@sl
altLabel
Martin Sadowski
@en
prefLabel
Martin J Sadowski
@ast
Martin J Sadowski
@en
Martin J Sadowski
@es
Martin J Sadowski
@nl
Martin J Sadowski
@sl
P106
P31
P496
0000-0002-3830-1779